Citations

Clear

273 citation(s) found for "Simone, N De".

Predicting Liberation from Continuous Kidney Replacement Therapy in Critically Ill Patients Using a Machine Learning Model
Alfieri, Francesca , Ancona, Andrea , Zappalá, Simone , Kashani, Kianoush

Mayo Clinic

Journal of the American Society of Nephrology | October 28, 2024 | Volume: 35 | Issue: 10S | Pages: No page available

10.1681/asn.202494h5jahd Get It

Prospective and External Evaluation of an Artificial Intelligence Model for Continuous and Early Prediction of Moderate and Severe AKI in Critically Ill Patients
Alfieri, Francesca , Ancona, Andrea , Zappalá, Simone , Maderna, Laura, Esteban, Federico , Gilavert, M. C., Bacci, Alessandro, Kashani, Kianoush , Votta, Carmine Domenico , Gómez, Josep , Bodí, María A. , Finazzi, Stefano , Bacci, Alessandro, Cauda, Valentina

Mayo Clinic

Journal of the American Society of Nephrology | October 28, 2024 | Volume: 35 | Issue: 10S | Pages: No page available

10.1681/asn.2024y4e76zq7 Get It

Predicting Persistent AKI Using Machine Learning: A Multicenter External Validation Study
Zappalá, Simone , Alfieri, Francesca , Ancona, Andrea , Kashani, Kianoush

Mayo Clinic

Journal of the American Society of Nephrology | October 28, 2024 | Volume: 35 | Issue: 10S | Pages: No page available

10.1681/asn.20244g6622p2 Get It

Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL
Aldoss, Ibrahim , Kopmar, Noam E. , Lin, Chenyu , Dekker, Simone E. , Gupta, Vishal, O’Connor, Timothy E. , Jeyakumar, Nikeshan , Muhsen, Ibrahim N. , Valtis, Yannis K. , Zhang, Amy , Miller, Kate , Ahmed, Mohamed , Schwartz, Marc S. , Tracy, Sean , Mukherjee, Akash , Ladha, Abdullah , Guzowski, Caitlin, Hoeg, Rasmus T. , Moore, Jozal , Connor, Matthew P. , Hill, LaQuisa C. , Tsai, Stephanie B., Sasine, Joshua , Solh, Melhem , Koura, Divya, Veeraputhiran, Muthu, Park, Jae H. , Bachanová, Veronika , Galal, Ahmed , Pullarkat, Vinod , Muffly, Lori , Oliai, Caspian , Yaghmour, George , Sutherland, Katherine, Zambrano, Héctor, Bradshaw, Danielle , Kubiak, Michal , Mountjoy, Luke , Malik, Shahbaz A. , Shaughnessy, Paul , Stefan, Maryann, O'Dwyer, Kristen M., Blunk, Betsy, Bishop, Michael R. , Aldoss, Ibrahim , Kopmar, Noam E , Lin, Chenyu , Gupta, Vishal K , Muhsen, Ibrahim N , Valtis, Yannis , Miller, Katharine , Chen, Evan , Mercadal, Santiago , Tracy, Sean I , Dholaria, Bhagirathbhai R , Battiwalla, Minoo , Logan, Aaron C , Ladha, Abdullah , Hilal, Talal , Connor, Matthew , Hill, LaQuisa C , Sasine, Joshua , Solh, Melham M , Kota, Vamsi , Frey, Noelle V , Park, Jae H , Luskin, Marlise R , Stock, Wendy , Cassaday, Ryan D , Muffly, Lori , Bachanova, Veronika , Roloff, Gregory W. , Ahmed, Naveed, Dykes, Kaitlyn C. , Schwartz, Marc, Dholaria, Bhagirathbhai , Battiwalla, Minoo , Hilal, Talal , Tsai, Stephanie B., Kota, Vamsi , Leonard, Jessica T , Frey, Noelle V. , Stock, Wendy , Cassaday, Ryan D. , Shah, Bijal , Faramand, Rawan , Oliai, Caspian H , Majhail, Navneet S. , Mathews, John Abraham , Advani, Anjali S. , O'Dwyer, Kristin , Lee, Catherine J , Bishop, Michael Russell

Mayo Clinic

Journal of Clinical Oncology | October 17, 2024 | Volume: 43 | Issue: 5 | Pages: 558-566

10.1200/jco.24.00321 | PMID 39418622 Get It

PURPOSE On the basis of the results of the ZUMA-3 trial, brexucabtagene autoleucel (brexu-cel), a CD19-directed chimeric antigen receptor T-cell therapy, gained US Food and Drug Administration approval in October 2021 for adults with relapsed/refractory (R/R) B-cell ALL (B-ALL). We report outcomes of patients treated with brexu-cel as a standard therapy. METHODS We developed a collaboration across 31 US centers to study adults with B-ALL who received brexu-cel outside the context of a clinical trial. Data were collected retrospectively from October 2021 to October 2023. Toxicities were graded per American Society for Transplantation and Cellular Therapy guidelines for cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS). RESULTS At the time of data lock, 204 patients had undergone apheresis and 189 were infused. Median follow-up time was 11.4 months. Forty-two percent of patients received brexu-cel in morphologic remission and would have been ineligible for participation in ZUMA-3. After brexu-cel, 151 achieved complete remission (CR), of which 79% were measurable residual disease (MRD) negative remissions. Median progression-free survival (PFS) was 9.5 months and median overall survival was not reached. Grade 3-4 CRS or ICANS occurred in 11% and 31%, respectively. In multivariable analysis, patients receiving consolidative hematopoietic cell transplantation (HCT; hazard ratio, 0.34 [95% CI, 0.14 to 0.85]) after brexu-cel had superior PFS compared with those who did not receive any consolidation or maintenance therapy. CONCLUSION Similar to ZUMA-3, high rates of MRD-negative CR were observed after brexu-cel treatment for R/R B-ALL. The use of HCT as consolidation after brexu-cel resulted in improved PFS.
The impact of multimorbidity on Quality of Life in inflammatory myopathies: A cluster analysis from the COVAD dataset
Fornaro, Marco , Venerito, Vincenzo , Pellico, Maria Rosa , Iannone, Florenzo , Joshi, Mrudula , Chen, Yi‐Ming , Tan, Ai Lyn , Saha, Sreoshy , Chatterjee, Tulika , Agarwal, Vishwesh , Kadam, Esha , Hasan, A T M Tanveer , Shumnalieva, Russka , Milchert, Marcin , Tan, Chou Luan , Vaidya, Binit , Kuwana, Masataka , Shaharir, Syahrul Sazliyana , Tehozol, Erick Adrian Zamora , Gutiérrez, Carlos Enrique Toro , Goo, Phonpen Akawatcharangura , Katchamart, Wanruchada , Parodis, Ioannis , Nikiphorou, Elena , Chinoy, Hector , Agarwal, Vikas , Gupta, Latika, Group, CoVAD Study, Sen, Parikshit, Javaid, Mahnoor, Andreoli, Laura, Lini, Daniele, Schreiber, Karen, Nune, Arvind, Tan, Ai Lyn, Patel, Aarat, Pauling, John D, Wincup, Chris, Barman, Bhupen, Torre, Ignacio García-De La, Colunga-Pedraza, Iris J, Merayo-Chalico, Javier, Chibuzo, Okwara Celestine, Kibbi, Lina El, Lilleker, James B, Salim, Babur, Gheita, Tamer, Saavedra, Miguel A, Griger, Zoltán, Kardes, Sinan, Vince, Melinda Nagy, Singh, Yogesh Preet, Ranjan, Rajiv, Jain, Avinash, Pandya, Sapan C, Pilania, Rakesh Kumar, Sharma, Aman, M, Manesh Manoj, Gupta, Vikas, Kavadichanda, Chengappa G, Patro, Pradeepta Sekhar, Ajmani, Sajal, Phatak, Sanat, Goswami, Rudra Prosad, Chowdhury, Abhra Chandra, Mathew, Ashish Jacob, Shenoy, Padnamabha, Asranna, Ajay, Bommakanti, Keerthi Talari, Shukla, Anuj, Pande, Arunkumar R, Chandwar, Kunal, Ghodke, Akanksha, Boro, Hiya, Fazal, Zoha Zahid, Vaidya, Binit, Cansu, Döndü Üsküdar, Yıldırım, Reşit, Gasparyan, Armen Yuri, Papa, Nicoletta Del, Sambataro, Gianluca, Fabiola, Atzeni, Govoni, Marcello, Parisi, Simone, Bocci, Elena Bartoloni, Sebastiani, Gian Domenico, Fusaro, Enrico, Sebastiani, Marco, Quartuccio, Luca, Franceschini, Franco, Sainaghi, Pier Paolo, Orsolini, Giovanni, Angelis, Rossella De, Danieli, Maria Giovanna, Grignaschi, Silvia, Giollo, Alessandro, Alunno, Alessia, Traboco, Lisa S, Wibowo, Suryo Anggoro Kusumo, Loarce-Martos, Jesús, Prieto-González, Sergio, Gonzalez, Raquel Aranega, Yoshida, Akira, Nakashima, Ran, Sato, Shinji, Kimura, Naoki, Kaneko, Yuko, Gono, Takahisa, Tomaras, Stylianos, Proft, Fabian Nikolai, Holzer, Marie-Therese, Gromova, Margarita Aleksandrovna, Aharonov, Or, Griger, Zoltán, Hmamouchi, Ihsane, bouchti, Imane El, Baba, Zineb, Giannini, Margherita, Maurier, François, Campagne, Julien, Meyer, Alain, Langguth, Daman, Limaye, Vidya, Needham, Merrilee, Srivastav, Nilesh, Hudson, Marie, Landon-Cardinal, Océane, Zuleta, Wilmer Gerardo Rojas, Arbeláez, Álvaro, Cajas, Javier, Silva, José António Pereira, Fonseca, João Eurico, Zimba, Olena, Ima-Edomwonyi, Uyi, Dedeke, Ibukunoluwa, Airenakho, Emorinken, Madu, Nwankwo Henry, Yerima, Abubakar, Olaosebikan, Hakeem, Becky, A, Koussougbo, Oruma Devi, Palalane, Elisa, So, Ho, Ugarte-Gil, Manuel Francisco, Chinchay, Lyn, Bernaola, José Proaño, Pimentel, Victorio, Fathi, Hanan Mohammed, Mohammed, Reem Hamdy A, Harifi, Ghita, Fuentes-Silva, Yurilís, Cabriza, Karoll, Losanto, Jonathan, Colaman, Nelly, Cachafeiro-Vilar, Antonio, Bautista, Generoso Guerra, Ho, Enrique Julio Giraldo, González, Raúl, Nunez, Lilith Stange, M, Cristian Vergara, Báez, Jossiell Then, Alonzo, Hugo, Pastelin, Carlos Benito Santiago, Salinas, Rodrigo García, Obiols, Alejandro Quiñónez, Chávez, Nilmo, Ordóñez, Andrea Bran, Argueta, Sandra, Llerena, Gil Alberto Reyes, Sierra-Zorita, Radames, Arrieta, Dina, Hidalgo, Eduardo Romero, Saenz, Ricardo, M, Idania Escalante, Morales, Roberto, Calapaqui, Wendy, Quezada, Ivonne, Arredondo, Gabriela, Pauling, John D , Wincup, Chris , Sambataro, Gianluca , Angelis, Rossella De , Loarce‐Martos, Jesus , Lini, Daniele , Fuentes-Silva, Yurilís , Giollo, Alessandro , Grignaschi, Silvia , Schreiber, Karen , Danieli, Maria Giovanna , Gupta, Latika , Shinjo, Samuel Katsuyuki , Hoff, Leonardo Santos , Kadam, Esha , Ziade, Nelly , Velikova, Tsvetelina , Hasan, A T M Tanveer , Shumnalieva, Russka , Milchert, Marcin , Tan, Chou Luan , Gracia-Ramos, Abraham Edgar , Cavagna, Lorenzo , Vaidya, Binit , Kuwana, Masataka , Sazliyana Shaharir, Syahrul , Knitza, Johannes , Makol, Ashima , Zamora Tehozol, Erick Adrian , Rojas Serrano, Jorge , Halabi, Hussein , Dey, Dzifa , Gutiérrez, Carlos Enrique Toro , Distler, Oliver , Katchamart, Wanruchada , Day, Jessica , Parodis, Ioannis , Nikiphorou, Elena , Chinoy, Hector , Agarwal, Vikas , Gupta, Latika , Joshi, Mrudula , Agarwal, Vishwesh , Tan, Ai Lyn , Chatterjee, Tulika , Pauling, John D , Wincup, Chris , Chen, Yi-Ming , Saha, Sreoshy , De Angelis, Rossella , Iannone, Florenzo , Shinjo, Samuel Katsuyuki , Ziadé, Nelly , Velikova, Tsvetelina , Gracia‐Ramos, Abraham Edgar , Makol, Ashima , Halabi, Hussein , Dey, Dzifa , Caballero‐Uribe, Carlo V. , Distler, Oliver , Day, Jessica , Group, CoVAD Study, Sen, Parikshit, Javaid, Mahnoor, Andreoli, Laura, Nune, Arvind, Tan, Ai Lyn, Patel, Aarat, Barman, Bhupen, Torre, Ignacio García-De La, Colunga-Pedraza, Iris J, Merayo-Chalico, Javier, Chibuzo, Okwara Celestine, Kibbi, Lina El, Lilleker, James B, Salim, Babur, Gheita, Tamer, Saavedra, Miguel A, Griger, Zoltán, Kardes, Sinan, Vince, Melinda Nagy, Singh, Yogesh Preet, Ranjan, Rajiv, Jain, Avinash, Pandya, Sapan C, Pilania, Rakesh Kumar, Sharma, Aman, M, Manesh Manoj, Gupta, Vikas, Kavadichanda, Chengappa G, Patro, Pradeepta Sekhar, Ajmani, Sajal, Phatak, Sanat, Goswami, Rudra Prosad, Chowdhury, Abhra Chandra, Mathew, Ashish Jacob, Shenoy, Padnamabha, Asranna, Ajay, Bommakanti, Keerthi Talari, Shukla, Anuj, Pande, Arunkumar R, Chandwar, Kunal, Ghodke, Akanksha, Boro, Hiya, Fazal, Zoha Zahid, Vaidya, Binit, Cansu, Döndü Üsküdar, Yıldırım, Reşit, Gasparyan, Armen Yuri, Papa, Nicoletta Del, Fabiola, Atzeni, Govoni, Marcello, Parisi, Simone, Bocci, Elena Bartoloni, Sebastiani, Gian Domenico, Fusaro, Enrico, Sebastiani, Marco, Quartuccio, Luca, Franceschini, Franco, Sainaghi, Pier Paolo, Orsolini, Giovanni, Alunno, Alessia, Traboco, Lisa S, Wibowo, Suryo Anggoro Kusumo, Prieto-González, Sergio, Gonzalez, Raquel Aranega, Yoshida, Akira, Nakashima, Ran, Sato, Shinji, Kimura, Naoki, Kaneko, Yuko, Gono, Takahisa, Tomaras, Stylianos, Proft, Fabian Nikolai, Holzer, Marie-Therese, Gromova, Margarita Aleksandrovna, Aharonov, Or, Griger, Zoltán, Hmamouchi, Ihsane, bouchti, Imane El, Baba, Zineb, Giannini, Margherita, Maurier, F. , Campagne, Julien, Meyer, Alain , Langguth, Daman, Limaye, Vidya, Needham, Merrilee, Srivastav, Nilesh, Hudson, Marie, Landon‐Cardinal, Océane , Zuleta, Wilmer Gerardo Rojas, Arbeláez, Álvaro, Cajas, Javier, Silva, José António Pereira, Fonseca, João Eurico, Zimba, Olena, Ima-Edomwonyi, Uyi, Dedeke, Ibukunoluwa, Airenakho, Emorinken, Madu, Nwankwo Henry, Yerima, Abubakar, Olaosebikan, Hakeem, Becky, A, Koussougbo, Oruma Devi, Palalane, Elisa, So, Ho, Ugarte-Gil, Manuel Francisco, Chinchay, Lyn, Bernaola, José Proaño, Pimentel, Victorio, Fathi, Hanan Mohammed, Mohammed, Reem Hamdy A, Harifi, Ghita, Cabriza, Karoll, Losanto, Jonathan, Colaman, Nelly, Cachafeiro-Vilar, Antonio, Bautista, Generoso Guerra, Ho, Enrique Julio Giraldo, González, Raúl, Nunez, Lilith Stange, M, Cristian Vergara, Báez, Jossiell Then, Alonzo, Hugo, Pastelin, Carlos Benito Santiago, Salinas, Rodrigo García, Obiols, Alejandro Quiñónez, Chávez, Nilmo, Ordóñez, Andrea Bran, Argueta, Sandra, Llerena, Gil Alberto Reyes, Sierra-Zorita, Radames, Arrieta, Dina, Hidalgo, Eduardo Romero, Saenz, Ricardo, M, Idania Escalante, Morales, Roberto, Calapaqui, Wendy, Quezada, Ivonne, Arredondo, Gabriela

Mayo Clinic

Rheumatology | September 26, 2024 | Volume: 64 | Issue: 4 | Pages: 2133-2142

10.1093/rheumatology/keae520 | PMID 39324556 Get It

Abstract Objective The presence of comorbidities can substantially affect patients’ quality of life, but data regarding their impact on idiopathic inflammatory myopathies (IIMs) are limited. Methods We examined the prevalence of comorbidities in IIM patients, other autoimmune rheumatic diseases (oAIRDs) and healthy controls (HCs), using data from the self-reported COVAD-2 survey. We defined basic multimorbidity (BM) as the presence of ≥2 non-rheumatic chronic conditions and complex multimorbidity (CM) as the presence of ≥3 non-rheumatic chronic conditions affecting ≥3 organ systems. Hierarchical clustering on principal components was performed for grouping. Results Among the COVAD respondents, 1558 IIMs, 4591 oAIRDs and 3652 HCs were analysed. IIMs exhibited a high burden of comorbidities (odds ratio [OR]: 1.62 vs oAIRDs and 2.95 vs HCs, P < 0.01), BM (OR: 1.66 vs oAIRDs and 3.52 vs HCs, P < 0.01), CM (OR: 1.69 vs AIRDs and 6.23 vs HCs, P < 0.01) and mental health disorders (MHDs) (OR: 1.33 vs oAIRDs and 2.63 vs HCs, P < 0.01). Among the IIM patients, those with comorbidities or MHDs had lower PROMIS Global Physical (PGP), PROMIS Global Mental (PGM), and PROMIS Physical Function (SF10) scores, and higher fatigue (F4a) scores (all P < 0.001). PGP, PGM, SF10a and F4a were influenced by age, active disease, BM and MHDs. Four distinct clusters were identified among the IIMs according to comorbidities and PROMIS scores. Conclusion Patients with IIMs have a higher burden of comorbidities that influence physical and mental health, identifiable as clinical clusters for optimized and holistic management approaches.
Telehealth vs In-Person Early Palliative Care for Patients With Advanced Lung Cancer
Greer, Joseph A. , El‐Jawahri, Areej , Rinaldi, Simone , Kamdar, Mihir , Horick, Nora , Pintro, Kedie, Rabideau, Dustin J. , Feliciano, Josephine , Leventakos, Konstantinos , Rabow, Michael W. , Zachariah, Finly , Martin, Sara , Silveira, Maria J. , Shoemaker, Laura, Bauman, Jessica R. , Spoozak, Lori , Grey, Carl, Blackhall, Leslie , Curseen, Kimberly , O’Mahony, Sean , Smith, Melanie , Rhodes, Ramona L. , Cullinan, Amelia , Jackson, Vicki A. , Investigators, REACH PC, Kamdar, Manali , Kamdar, Manali , Temel, Jennifer S. , Park, Elyse R , Schwamm, Lee H. , Chua, Isaac S. , Fischer, Stacy M. , Campbell, Toby C. , Hanson, Laura C. , Bakitas, Marie , Investigators, REACH PC, Horick, Nora

Mayo Clinic

JAMA | September 11, 2024 | Volume: 332 | Issue: 14 | Pages: 1153

10.1001/jama.2024.13964 | PMID 39259563 Get It

Importance Numerous studies show that early palliative care improves quality of life and other key outcomes in patients with advanced cancer and their caregivers, although most lack access to this evidence-based model of care. Objective To evaluate whether delivering early palliative care via secure video vs in-person visits has an equivalent effect on quality of life in patients with advanced non–small cell lung cancer (NSCLC). Design, Setting, and Participants Randomized, multisite, comparative effectiveness trial from June 14, 2018, to May 4, 2023, at 22 US cancer centers among 1250 patients within 12 weeks of diagnosis of advanced NSCLC and 548 caregivers. Intervention Participants were randomized to meet with a specialty-trained palliative care clinician every 4 weeks either via video visit or in person in the outpatient clinic from the time of enrollment and throughout the course of disease. The video visit group had an initial in-person visit to establish rapport, followed by subsequent virtual visits. Main Outcomes and Measures Equivalence of the effect of video visit vs in-person early palliative care on quality of life at week 24 per the Functional Assessment of Cancer Therapy-Lung questionnaire (equivalence margin of ±4 points; score range: 0-136, with higher scores indicating better quality of life). Participants completed study questionnaires at enrollment and at weeks 12, 24, 36, and 48. Results By 24 weeks, participants (mean age, 65.5 years; 54.0% women; 82.7% White) had a mean of 4.7 (video) and 4.9 (in-person) early palliative care encounters. Patient-reported quality-of-life scores were equivalent between groups (video mean, 99.7 vs in-person mean, 97.7; difference, 2.0 [90% CI, 0.1-3.9]; P = .04 for equivalence). Rate of caregiver participation in visits was lower for video vs in-person early palliative care (36.6% vs 49.7%; P < .001). Study groups did not differ in caregiver quality of life, patient coping, or patient and caregiver satisfaction with care, mood symptoms, or prognostic perceptions. Conclusions and Relevance The delivery of early palliative care virtually vs in person demonstrated equivalent effects on quality of life in patients with advanced NSCLC, underscoring the considerable potential for improving access to this evidence-based care model through telehealth delivery. Trial Registration ClinicalTrials.gov Identifier: NCT03375489
Unconstrained Precision Mitochondrial Genome Editing with αDdCBEs
Restrepo-Castillo, Santiago , Simone, Brandon W. , Castillo, Santiago R , Devaux, Patricia , Clark, Karl J. , Ekker, Stephen C.

Mayo Clinic

Human Gene Therapy | August 30, 2024 | Volume: 35 | Issue: 19-20 | Pages: 798-813

10.1089/hum.2024.073 | PMID 39212664 Get It

DddA-derived cytosine base editors (DdCBEs) enable the targeted introduction of C•G-to-T•A conversions in mitochondrial DNA (mtDNA). DdCBEs work in pairs, with each arm composed of a transcription activator-like effector (TALE), a split double-stranded DNA deaminase half, and a uracil glycosylase inhibitor. This pioneering technology has helped improve our understanding of cellular processes involving mtDNA and has paved the way for the development of models and therapies for genetic disorders caused by pathogenic mtDNA variants. Nonetheless, given the intrinsic properties of TALE proteins, several target sites in human mtDNA are predicted to remain out of reach to DdCBEs and other TALE-based technologies. Specifically, due to the conventional requirement for a thymine immediately upstream of the TALE target sequences ( i.e. , the 5′-T constraint), over 150 loci in the human mitochondrial genome are presumed to be inaccessible to DdCBEs. Previous attempts at circumventing this requirement, either by developing monomeric DdCBEs or utilizing DNA-binding domains alternative to TALEs, have resulted in suboptimal specificity profiles with reduced therapeutic potential. Here, aiming to challenge and elucidate the relevance of the 5′-T constraint in the context of DdCBE-mediated mtDNA editing, and to expand the range of motifs that are editable by this technology, we generated DdCBEs containing TALE proteins engineered to recognize all 5′ bases. These modified DdCBEs are herein referred to as αDdCBEs. Notably, 5′-T-noncompliant canonical DdCBEs efficiently edited mtDNA at diverse loci. However, they were frequently outperformed by αDdCBEs, which exhibited significant improvements in activity and specificity, regardless of the most 5′ bases of their TALE binding sites. Furthermore, we showed that αDdCBEs are compatible with the enhanced DddA tox variants DddA6 and DddA11, and we validated TALE shifting with αDdCBEs as an effective approach to optimize base editing outcomes. Overall, αDdCBEs enable efficient, specific, and unconstrained mitochondrial base editing.
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL
Aldoss, Ibrahim , Roloff, Gregory W. , Kopmar, Noam E. , Lin, Chenyu , Advani, Anjali S. , Dekker, Simone E. , O’Connor, Timothy E. , Jeyakumar, Nikeshan , Muhsen, Ibrahim N. , Valtis, Yannis K. , Zhang, Amy , Miller, Katharine, Sutherland, Katherine C. , Ahmed, Mohamed , Zambrano, Héctor, Bradshaw, Danielle , Schwartz, Marc S. , Tracy, Sean , Kubiak, Michal Jakub , Mukherjee, Akash , Mountjoy, Luke , Malik, Shahbaz A. , Shaughnessy, Paul , Ladha, Abdullah , Stefan, Maryann, Guzowski, Caitlin, Hoeg, Rasmus T. , Moore, Jozal , Connor, Matthew P. , O’Dwyer, Kristen M. , Hill, LaQuisa C. , Tsai, Stephanie B., Sasine, Joshua , Solh, Melhem , Koura, Divya, Veeraputhiran, Muthu, Blunk, Betsy, Oliai, Caspian , Park, Jae H. , Bachanová, Veronika , Galal, Ahmed , Bishop, Michael R. , Pullarkat, Vinod , Muffly, Lori , Lin, Chenyu , Advani, Anjali S , Jeyakumar, Nikeshan , Dykes, Kaitlyn C , Chen, Evan , Bradshaw, Danielle , Dholaria, Bhagirathbhai R , Majhail, Navneet S , Logan, Aaron C , Ladha, Abdullah , Hilal, Talal , Moore, Jozal , Connor, Matthew , Hill, LaQuisa C , Sasine, Joshua , Lee, Catherine J , Leonard, Jessica T , Frey, Noelle V , Luskin, Marlise R , Muffly, Lori , Bachanova, Veronika , Aldoss, Ibrahim , Muhsen, Ibrahim N , Sutherland, Katherine , Roloff, Gregory W , Faramand, Rawan , Gupta, Vishal , Dykes, Kaitlyn C. , Mercadal, Santiago , Schwartz, Marc, Dholaria, Bhagirathbhai , Majhail, Navneet S. , Battiwalla, Minoo , Mathews, John, Hilal, Talal , O'Dwyer, Kristin , Tsai, Stephanie B., Kota, Vamsi , Oliai, Caspian H , Frey, Noelle V. , Bishop, Michael Russell , Stock, Wendy , Cassaday, Ryan D. , Shah, Bijal

Mayo Clinic

Blood Advances | August 2, 2024 | Volume: 8 | Issue: 23 | Pages: 6139-6147

10.1182/bloodadvances.2024013747 | PMID 39093952 Get It

Abstract The effect of prior inotuzumab ozogamicin (InO) treatment on brexucabtagene autoleucel (brexu-cel) outcomes remains unclear in adults with acute lymphoblastic leukemia (ALL). We conducted a retrospective multicenter analysis of 189 patients with relapsed/refractory ALL treated with brexu-cel. Over half of the patients received InO before brexu-cel (InO exposed). InO-exposed patients were more heavily pretreated (P = .02) and frequently had active marrow disease before apheresis (P = .03). Response rate and toxicity profile after brexu-cel were comparable for InO-exposed and InO-naïve patients; however, consolidation therapy after brexu-cel response was used at a higher rate in InO-naïve patients (P = .005). With a median follow-up of 11.4 months, InO-exposed patients had inferior progression-free survival (PFS; P = .013) and overall survival (OS; P = .006) in univariate analyses; however, prior InO exposure did not influence PFS (hazard ratio, 1.20; 95% confidence interval, 0.71-2.03) in multivariate models. Within InO-exposed patients, InO responders had superior PFS (P = .002) and OS (P < .0001) relative to InO-refractory patients. The timing of administering InO did not affect brexu-cel outcomes, with comparable PFS (P = .51) and OS (P = .86) for patients receiving InO as bridging therapy or before apheresis. In conclusion, although InO exposure was associated with inferior survival outcomes after brexu-cel in unadjusted analyses, these associations were no longer significant in multivariate analyses, suggesting it is unlikely that InO negatively affects brexu-cel efficacy. Our data instead imply that InO-exposed recipients of brexu-cel tend to be higher-risk patients with intrinsic adverse leukemia biology.
Vigorous Exercise in Patients With Congenital Long QT Syndrome: Results of the Prospective, Observational, Multinational LIVE-LQTS Study
Lampert, Rachel , Day, Sharlene M. , Ainsworth, Barbara E. , Burg, Matthew M. , Marino, Bradley S. , Salberg, Lisa , Tome, Maite , Abrams, Dominic J. , Aziz, Peter F. , Barth, Cheryl , Behr, Elijah R. , Bell, Cheyanne , Berul, Charles I. , Bos, J. Martijn , Cannom, David S. , Cannon, Bryan C. , Concannon, Maryann, Czosek, Richard J. , Dubin, Anne M. , Dziura, James , Erickson, Christopher C. , Etheridge, Susan P. , Gray, Belinda , Haglund-Turnquist, Carla , Johnsrude, Christopher L. , Lara, Alice, Saarel, Elizabeth V. , Sanatani, Shubhayan , Shah, Maully J. , Simone, Laura, Tomaselli, Gordon F., Ware, James S. , Zaręba, Wojciech , Ackerman, Michael J. , Day, Sharlene , Burg, Matthew , Tome Esteban, Maria Teresa , Bos, Johan M , Cannon, Bryan C , Cerrone, Marina , Czosek, Richard J , Dubin, Anne M , Dziura, James , Erickson, Christopher C , Estes, N.A. Mark , Etheridge, Susan P , Goldenberg, Ilan , Gray, Belinda , Haglund-Turnquist, Carla M , Harmon, Kimberly G , James, Cynthia A , Johnsrude, Christopher , Kannankeril, Prince J , Law, Ian H , Link, Mark S. , Molossi, Silvana M , Olshansky, Brian , Noseworthy, Peter A , Saarel, Elizabeth V , Sanatani, Shubhayan , Shah, Maully , Skinner, Jonathan R , Ware, James S , Webster, Gregory , Zareba, Wojciech , Zipes, Douglas P , Ackerman, Michael J , Behr, Elijah Raphael , Abrams, Dominic J , Bradley, David J. , Cerrone, Marina , Goldenberg, Ilan , Harmon, Kimberly G. , James, Cynthia A. , Kannankeril, Prince J. , Law, Ian H. , Li, Fangyong , Olshansky, Brian , Noseworthy, Peter A. , Skinner, Jonathan R. , Webster, Gregory , Zipes, Douglas P.

Mayo Clinic

Circulation | July 25, 2024 | Volume: 150 | Issue: 7 | Pages: 516-530

10.1161/circulationaha.123.067590 | PMID 39051104 Get It

BACKGROUND: Whether vigorous exercise increases risk of ventricular arrhythmias for individuals diagnosed and treated for congenital long QT syndrome (LQTS) remains unknown. METHODS: The National Institutes of Health–funded LIVE-LQTS study (Lifestyle and Exercise in the Long QT Syndrome) prospectively enrolled individuals 8 to 60 years of age with phenotypic and/or genotypic LQTS from 37 sites in 5 countries from May 2015 to February 2019. Participants (or parents) answered physical activity and clinical events surveys every 6 months for 3 years with follow-up completed in February 2022. Vigorous exercise was defined as ≥6 metabolic equivalents for >60 hours per year. A blinded Clinical Events Committee adjudicated the composite end point of sudden death, sudden cardiac arrest, ventricular arrhythmia treated by an implantable cardioverter defibrillator, and likely arrhythmic syncope. A National Death Index search ascertained vital status for those with incomplete follow-up. A noninferiority hypothesis (boundary of 1.5) between vigorous exercisers and others was tested with multivariable Cox regression analysis. RESULTS: Among the 1413 participants (13% <18 years of age, 35% 18–25 years of age, 67% female, 25% with implantable cardioverter defibrillators, 90% genotype positive, 49% with LQT1, 91% were treated with beta-blockers, left cardiac sympathetic denervation, and/or implantable cardioverter defibrillator), 52% participated in vigorous exercise (55% of these competitively). Thirty-seven individuals experienced the composite end point (including one sudden cardiac arrest and one sudden death in the nonvigorous group, one sudden cardiac arrest in the vigorous group) with overall event rates at 3 years of 2.6% in the vigorous and 2.7% in the nonvigorous exercise groups. The unadjusted hazard ratio for experience of events for the vigorous group compared with the nonvigorous group was 0.97 (90% CI, 0.57–1.67), with an adjusted hazard ratio of 1.17 (90% CI, 0.67–2.04). The upper 95% one-sided confidence level extended beyond the 1.5 boundary. Neither vigorous or nonvigorous exercise was found to be superior in any group or subgroup. CONCLUSIONS: Among individuals diagnosed with phenotypic and/or genotypic LQTS who were risk assessed and treated in experienced centers, LQTS-associated cardiac event rates were low and similar between those exercising vigorously and those not exercising vigorously. Consistent with the low event rate, CIs are wide, and noninferiority was not demonstrated. These data further inform shared decision-making discussions between patient and physician about exercise and competitive sports participation. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02549664.